<DOC>
	<DOC>NCT00496275</DOC>
	<brief_summary>To test the safety and tolerability of ZD6474 in combination withVinorelbine (Navelbine) or Gemcitabine (Gemzar) plus cisplatin as first line therapy in patients with locally advanced or metastatic (Stage IIIB-IV) Non Small Cell Lung Cancer.</brief_summary>
	<brief_title>Phase I Combination With Vinorelbine or Gemcitabine Plus Cisplatin in Locally Advanced or Metastatic NSCLC</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Confirmed non small cell lung cancer (stage IIIBIV) Life expectancy greater than 12 weeks At least 1 measurable lesion greater than 10mm in smallest diameter. Prior treatment with anticancer agent Brain metastases Major surgery within last 4 weeks</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>ZACTIMA</keyword>
</DOC>